Assistant Professor of Psychiatry
Brian P. Brennan, M.D., is an assistant professor of psychiatry at Harvard Medical School and is currently the Director of Medical Research at the Obsessive-Compulsive Disorder Institute at McLean Hospital and the Associate Director of Translational Neuroscience Research in the Biological Psychiatry Laboratory at McLean Hospital. He received his medical degree from the Raymond and Ruth Perelman School of Medicine (formerly known as the University of Pennsylvania School of Medicine) and completed residency training in the combined Massachusetts General Hospital/McLean Hospital Psychiatry Residency Training Program.
The overarching theme of Dr. Brennan's research is the investigation of novel biological targets for the development of improved pharmacologic therapies for mood and anxiety disorders. Specifically, Dr. Brennan focuses on the use of neuroimaging as a means to better understand the mechanism of action of both standard and novel treatments for mood and anxiety disorders and to identify neurochemical and functional mediators of treatment response.
Dr. Brennan's clinical and research work has led to grant funding from the National Institute of Mental Health, NARSAD, the Sidney R. Baer, Jr. Foundation, and the Stanley Medical Research Institute and receipt of the Outstanding Professional of the Year Award from the Boston Chapter of the Depression and Bipolar Disorder Support Alliance.
Grants and Funding: We proudly support the research and programs of 501(c)(3) non-profit organizations and institutions such as: the Anxiety Disorders program of the Jane & Terry Semel Institute for Neuroscience & Human Behavior at the University of California, Los Angeles; the Pacific Institute of Medical Research; the International Foundation for Research and Education on Depression (iFred); and SchoolsForHope.org, an iFred educational project. Working with these partners enables Anxiety.org to extend its commitment to its mission. All the donations received, as well as 100% of Anxiety.org revenue in 2017, will be contributed to build, develop, and further the understanding, investigation, discovery, and treatment of the full spectrum of anxiety and related disorders.